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Graves’ disease (GD) and ophthalmopathy (GO) are organ-speciﬁc autoimmune-inﬂammatory disorders characterized by a
complex pathogenesis. The inﬂammatory process is dominated by an imbalance of the antioxidant-oxidant mechanism, increased
production of radical oxygen species (ROS), and cytokines which sustain the autoimmune process and perpetuate the disease.
Recently, selenium, which is a powerful antioxidant, has been successfully applied in patients with mild GO, slowing the
progression of disease, decreasing the clinical activity score, and appreciably improving the quality of life. The mechanisms
of selenium action are variable. The aim of this review is to summarize the actions of selenium in GD and GO. Selenium as
selenocysteine is incorporated in selenoproteins, such as glutathione peroxidase which catalyzes the degradation of hydrogen
peroxide and lipid hydroperoxide that are increasingly produced in hyperthyroidism. Moreover, selenium decreases the formation
of proinﬂammatory cytokines, while it contributes, in synergy with antithyroid drugs, to stabilization of the autoimmune process
in GD and alleviation of GO. It is now to be clariﬁed whether enforced nutritional supplementation has the same results and
whether prolonging selenium administration may have an impact on the prevention of disease.
1.Introduction
Observed and brieﬂy described, though not published, by
Parry in the late 1700s, Graves’ disease (GD) was deﬁnitively
identiﬁed and documented by Robert Graves in 1835 and
classically described by von Basedow in 1840 [1–3]. GD is
an autoimmune disease characterized by the activation of
autoantibodies against the TSH receptor (TRAB), leading to
excessive thyroid hormone production [4]. GD manifests,
interalia, via thyrotoxicosis and extrathyroid involvement
often entailing orbitopathy (GO) and, rarely, dermopathy
(pretibial myxedema) and acropathy. Moreover, the TRAB,
by stimulating cyclic adenosine monophosphate (AMP),
cause proliferation and hyperplasia of the thyroid follicular
cells resulting in enlargement of the gland, frequently the
ﬁrst sign of the disease, the swelling ranging from slight
to marked [5]. Clinically, the thyroid is ﬁrm in consistency
and tender in patients with a greatly enlarged goiter, while
palpation lobulations are also commonly detected which can
be mistaken for nodules.
No single gene has been pinpointed as causing GD, a
disease which is most prevalent in women between the ages
of 20 and 50 years. However, it has been associated with
certain MHC Class II HLA alleles depending on the racial
group, for example, HLA-DR3 in whites [4]. An association
of GD with polymorphisms of the cytotoxic T-lymphocyte
antigen 4 (CTLA-4) gene has also been established, suggest-
ing a functional role of CTLA-4 in autoreactive T cells [4, 5].
A combination of genetic and environmental factors is
responsible for the initiation of autoimmunity. Interactions
between genetic and environmental factors are underscored
by the existing associations linking age at diagnosis, goiter,
disease severity, smoking, and family history [6]. In addi-
tion, iodine repletion in iodine-deﬁcient areas is usually
accompanied by an increased incidence of GD due to the
Jod-Basedow phenomenon. Stress is also thought to be a
signiﬁcant factor precipitating GD in susceptible individuals
[7], while smoking is well established as being linked to GO
but not to GD [8].
Treatment modalities of GD consist of administration of
antithyroid drugs, radioiodine therapy, or surgery. Radioio-
dine therapy, is favored only in USA, whereas antithyroid
drugs, including methimazole, carbimazole, and propylth-
iouracil, comprise ﬁrst choice treatment in the rest of the2 Journal of Thyroid Research
world. Nevertheless, according to a recent study examining
the frequency of antithyroid drug prescription in USA,
methimazole (MMI) has lately become the most frequently
prescribed antithyroid drug, indicating a clear shift towards
pharmacological treatment as the primary treatment option
in GD [9]. Treatment should be planned for a period of at
least12months,andpatientsareusuallybecomingeuthyroid
within this timeframe; nevertheless, the duration of the
remissionperiodisunpredictable,sincethediseaseismarked
by cycles of remission and relapse of variable duration [4].
Recently, evidence has emerged indicating that selenium
administration could be eﬀective and safe in patients with
GD and with mild forms of GO [10].
The aim of this paper is to brieﬂy evaluate the current
knowledge concerning the pathogenesis of GD and GO and
discuss the evolving role of selenium within the context of
its potential as a therapeutic means of intervention in these
disorders.
2. Pathogenesis of GDandGO
Hyperthyroidism is caused by the binding of TSH-stimu-
lating antibodies to the TSH receptor, a G-protein-coupled
receptor. However, the ﬁrst step in this process is considered
to be precipitation by environmental factors of an HLA-
related organ-speciﬁc defect in suppressor T-lymphocyte
function [5]. This leads to decreased suppression of thyroid-
directed helper T-lymphocytes which, in the presence of
dendritic cells and macrophages, produce the cytokines γ-
interferon (IFNγ) and interleukin-1 (IL-1), subsequently
diﬀerentiating B cells to plasma cells and generating TRAB.
Concomitantly, IFNγ enhances the expression of HLA-DR
antigensonthesurfaceofthyroidcells(Figure 1).Thus,IFNγ
modulates the autoimmune process and, by stimulating
chemokine production bythyroidfollicularcells,contributes
to the maintenance of the autoimmune process [10]. The
contribution of dendritic cells and B cells is apparently
crucial for the initiation of disease since they express the
costimulatory molecules, CD80 and CD86, that are key
triggers for the reaction of T lymphocytes to thyroid cell
presenting antigens [4]. TRAB stimulate the TSHR on the
thyroid follicular cells, resulting in increased thyroid hor-
moneproduction,whichmayfurtherreducethenumberand
functionofsuppressorTlymphocytesandstimulatehelperT
lymphocyte, thus, perpetuating the cyclicity of disease [4, 5].
GO is a complex autoimmune disease. Whereas the
cycle of GD consists of two components, immunological
and hormonal, that perpetuate the process, the progression
of GD to GO, and rarely to dermopathy, is likely to be
a positive feedback cycle composed of three interrelated
components: mechanical, immunological, and cellular [5].
Comprehensive reviews on the pathophysiology of GO
have recently been published [11–14]. Brieﬂy, the loss of
tolerance of T cells to the TSHR, via as yet unknown
mechanisms, ignites the autoimmune process. The TSHR
is internalized and presented by antigen-presenting cells to
helper T cells. Subsequently, the TRAB, which are secreted
by activated B cells, recognize the TSHR on the ﬁbroblasts
of the orbita, where they initiate the ocular changes [12,
13]. The ﬁbroblasts have been recognized as target cells in
GO. Orbital ﬁbroblasts stimulated by IFNγ, tumor necrosis
factor-α (TNF-α), growth factors and oxygen reactive species
(ROS), secrete hyaluronic acid, and prostaglandin E2, known
mediators of inﬂammation, while a subgroup may diﬀer-
entiate into mature adipocytes presenting TSHR [13, 14].
The subsequent proliferation of adipocytes and ﬁbroblasts
results in increased synthesis of glycosaminoglycans (GAG),
which causes edema of orbital structures, extraocular muscle
enlargement, and adipose tissue expansion; these events are
constituting the signs of disease [15].
Concerning the recent enquiry as to whether autoimmu-
nity against IGF-1R is primarily involved in the pathogenesis
of GO, it is likely that it is not speciﬁc but instead constitutes
a secondary reaction of the autoimmune process [16]
The mechanisms promoting oxidative stress have also
beenimplicatedinthepathogenesisofGO.Hyperthyroidism
increases oxidants and decreases antioxidants leading to
oxidative stress, this process is dominated by the production
of ROS which have long been recognized as intermediates
of various essential biological redox reactions [17, 18]. The
adverse eﬀects induced by ROS have been suggested as being
partly responsible for the tissue injury. Mitochondria are
a major source of superoxide anion (O2
−) and hydrogen
peroxides (H2O2), while a number of intracellular enzymes,
xanthine oxidase being the best known, are involved in
oxidation reactions in which molecular oxygen (O2)i s
reduced to O2
− [19].
Ongoing autoimmunity may contribute to increased
oxidative stress even in euthyroid GD patients, while patients
who have relapsed present increased markers of oxidative
stress [20]. Moreover, the content of 8-hydroxy 2 -deoxy-
guanosine (8-OHdG), an important biomarker of oxidative
DNA damage, was found signiﬁcantly higher in orbital
ﬁbroblasts together with O2
− and H2O2, underscoring the
major role that ROS play in the pathogenesis of GO [21].
Recently, increased 11β-hydroxysteroid dehydrogenase
(11β-HSD1)expression,inducedbycytokines,wasdescribed
in orbital adipose cells, a condition leading to elevated local
generation of cortisol by 11β-HSD1, which may suppress
cytokine synthesis and resolve the inﬂammation [22]. 11β-
HSD1 activates cortisone to cortisol in peripheral and
visceral adipose tissues. According to the authors, since
failure to produce adequate levels of local glucocorticoids in
the orbita may signify persistence of the disease, 11β-HSD1
could provide a new therapeutic target of disease [22].
3. Presentationand Treatment
N o v el tie so fGDan dGO
TRAB levels in serum are pathognomonic for GD, predicting
the course of disease and response to antithyroid treatment;
they do not, on the other hand, predict the development of
GO [23]. In conjunction with the high levels of TRAB, the
risk of relapse is related to young age, male gender, and large
goiter [24]. Tobacco smoking has been consistently linked






































Figure 1: (a) Schematic presentation of the cascade of events in the pathogenesis of Graves’ ophthalmopathy. Secretion of cytokines, such
as IFN-γ and IL-2, by activated helper cells result in activation of B cells and secretion of TSH receptor antibodies. These bind to the TSH
receptor in the orbital ﬁbroblast and on the thyroid follicular cells, thereby, extending muscle enlargement resulting in oedema. (b) Selenium
by suppressing cytokines production considerably attenuates the inﬂammation leading to alleviation of symptoms and signs. Abbreviations:
HLA: human leukocyte antigen; APC: antigen presenting cell; IFN-γ: interferon-γ; IL-1: interleukin-1; TRAB: TSH-receptor antibodies;
GAG: glycosaminoglycans.
treatment for GD is associated with a worsening of GO,
patients, and particularly those who are smokers, should
be administered oral steroids [26]. Interestingly, a recent
study from Varese has suggested that steroid prophylaxis
can be achieved by applying lower prednisone doses, that
is, 0.2mg/kg BW, than had previously been reported [27].
Moreover, RAI when applied for treatment for GD results
more frequently in aggravation or appearance of GO than
after antithyroid treatment [28]. Nevertheless, choice of the
best treatment for hyperthyroidism in patients with active
GO remains a dilemma [29]. In a recent prospective analysis
of the data of 108 patients with Graves’ hyperthyroidism and
severe orbitopathy, it was reported that prolonged treatment
applying partial block therapy with low-dose thionamides
plus LT4, over a median duration of 80 months, led to
euthyroidismandstabilizedtheorbitopathy[30].Withinthis
context, a retrospective study proposes block-replacement
treatment of GD patients with GO as a feasible treatment
option until the orbitopathy becomes inactive, and no
further treatment is required [31].
Neither antithyroid drug treatment nor thyroidectomy
has any impact on the course of GO, and treatment in the
active phase is based on the clinical activity score (CAS) [32,
33]; introduced by Mourits et al. in 1989, the CAS remains
a reliable and easily applied scoring system enabling the
classiﬁcation of patients into those with active or inactive
disease [33].
Recently, rituximab, a CD-20 antibody which blocks the
diﬀerentiation of B cells and potentially inhibits B-cells-
mediated immunity, was applied with encouraging results
in patients with GO [34]. The compound was shown to
i m p r o v eG Ow i t h o u t ,h o w e v e r ,a ﬀecting the TRAB levels
[35]. Serum cytokine IL-6 levels did not change, while
chemokineligand10(CXCL10)increasedatB-celldepletion.
Basedontheknowledgeofthecrucialroleoftheoxidants
in the pathogenesis of GD as well as in the development
of GO, several studies have been conducted administrating
antioxidants as the treatment modality in patients with GD
and GO.
In a nonrandomized study, 82% of the 11 patients
with active GO responded to antioxidant treatment with
nicotinamide and allopurinol as compared to only 27%
of the control group. Soft tissue inﬂammation parameters
responded better than any other component of disease [36].
Supplementation with a mixture of antioxidants, includ-
ing selenium, beta-carotene, and vitamins C and E, in
addition to methimazole, in 29 patients with GD led to
euthyroidism faster than in 28 patients taking only methi-
mazole and who served as the control group [37]. Serum
selenium levels as well as glutathione peroxidase activity
were statistically signiﬁcantly elevated in the supplemented
patients, validating treatment with antioxidants, especially
when this incorporated selenium.
In a more recent, randomized, double-blind, and place-
bo-controlled study recruiting 159 patients with mild GO,
the eﬀects of selenium administration for 6 months in the
form of selenite were assessed versus an anti-inﬂammatory
agent [10]. Selenium improved quality of life and sig-
niﬁcantly slowed the progression of GO, while it greatly
decreasedtheCASwhencomparedwiththepentoxifyllineor4 Journal of Thyroid Research
placebo group. A 6-month followup conﬁrmed the results of
the 6-month treatment. The authors hypothesized a reversal
of the disturbed antioxidant-oxidant balance in GD and GO
although the exact mechanisms of selenium action are not
elucidated.
In another study assessing the selenium levels in patients
going into remission (n = 24) and relapses (n = 59),
no statistically signiﬁcant diﬀerences were detected between
the two groups. However, patients in remission of GD had
the highest (>120μg/L) serum selenium levels, while it is
of interest that TRAB levels and selenium were negatively
correlated [38].
4. Mechanismsof Selenium
Action in GD andGO
Selenium is vital for a wide range of biological processes;
hence,thestateof“selenostasis”isessentialforwellbeingand
human health [39]. The many biological and clinical beneﬁts
conferred by selenium are achieved by virtue of its remark-
able antioxidative eﬀects mediated mainly by the selenopro-
teins GPx and TRx reductase. TRx is a stress- and iodine-
inducedprotein, possessing strongredoxactivities,andithas
been postulated that it may be implicated in the regulation
of T3 production in GD. It has been reported highly
produced in GD and expressed in the thyroid follicular cells.
Nevertheless, its precise role, though of considerable interest
due to its characteristics, remains as yet unraveled [40].
The hypermetabolic state in acute GD, the intracellular
ATP, and increased oxygen consumption lead to mitochon-
dria dysfunction, which generates ROS and disrupts the
oxidant and antioxidant balance, thereby, causing oxidative
stress and tissue injury [41]. By activating GPxs, selenium
ignites the “second line” of antioxidant defense, behind
the enzymatic “ﬁrst line” defense system composed of
the superoxide dismutase (SOD) and catalase (CAT) [42].
Thus, SOD and CAT synthesize an eﬃcient antioxidative
mechanismcapableofneutralizingthebiologic eﬀectsoffree
radicals;whenthismechanismissaturated,the“secondline,”
regulated by selenium availability, is activated. Experimental
studies in hyperthyroidism have documented an enhanced
activity of the TRx and GPx systems, stimulated by the
calcium phosphatidylinositol cascade which is usually acti-
vated in hyperthyroidism, as well as increased levels of SOD
and of glutathione in erythrocytes [43, 44]. These ﬁndings
provide evidence of an upregulation of the antioxidative
and protective systems in acute GD, depending, however,
on the duration and severity of the disease; these system(s)
might become saturated, following which supplementation
or nutritional intervention is required.
The induced oxidative stress enﬂames lipid peroxidation
and activates various inﬂammatory pathways. ROS may
stimulate the NF-κB pathway, a cornerstone of immune
and inﬂammatory response, which has been associated with
increased production of TNF-α and IL-6 cytokines [45].
Selenium inhibits NF-κB from binding to its gene promoters
andconsequentlydiminishescytokineproductionandatten-
uates the inﬂammation; by contrast, selenium is likely not to
interfere with the translocation of NF-κB and its subunits to
the nucleus [46]. This could be one of the most important
anti-inﬂammatory eﬀects of selenium supplementation and
thus be of potential beneﬁt for patients suﬀering from GD
and, especially, GO.
In GO, the balance of T helper (Th) 1/Th2 lymphocytes
shiftstoaprevalenceofTh1typeCD4+,whichplaysapivotal
role in the development of disease [47]. Consequently,
the ratio Th1/Th2 has been proposed as a biomarker of
disease activity and as a target for speciﬁc immune therapy
of GO. The subsequent overproduction of cytokines, such
as TNF-α and IFNγ, sustains the inﬂammatory process.
It is of interest that treatment with a mixture containing
selenium-suppressed Th1 while upregulating Th2 [48]. Th1
predominate in eye muscles (EM) and IFN-γ,T N F - α,I L -
1β, and IL-6 mRNA have been abundantly detected in EM
in contrast to orbit fat where IL-4 and IL-10 mRNA, with
signiﬁcant variations within patients, were more frequently
detected [49]. Thus, mediated by the suppression of Th1-like
cytokines, selenium alleviates the soft tissue inﬂammation
and improves eye motility.
ROS, such as H2O2, may also activate p38 mitogen-
activated protein kinase (p38MAPK) and induce expression
of high levels of cyclooxygenase (COX)-2; this reaction is
depending on the severity of GO, in orbital ﬁbroadipose
tissues [50]. Recently, it has been shown that selenium
w a sa b l et or e d u c eH 2O2-mediated expression of COX-2
in vascular endothelial cells by inhibiting the p38 MAPK
pathway [51].
In summary, selenium inﬂuences the inﬂammatory pro-
cess in GD and GO by inhibiting various pathways though
its mechanism of action is not completely clariﬁed. It is
nonetheless possible that, in synergy with antithyroid drugs
or immune modulators, selenium might oﬀer an alternative
therapeutic approach in patients with severe disease. It
also remains to be established whether enforced nutritional
supplementationhasthesameeﬀectsandwhetherlong-term
selenium administration in the form of selenomethionine
or as nutritional intervention may have an impact on the
incidence of relapse of GD and GO.
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